Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET.
A live webcast of the fireside chat will be available on the investors section of the Talaris website at www.talaristx.com. After the live webcast, the event will remain archived on the Talaris website for 30 days.
About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
Media Contact
Marin Bergman
Ten Bridge Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
(818) 516-2746
Investor Contact
Chris Brinzey
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
(339) 970-2843
| Last Trade: | US$20.65 |
| Daily Change: | 0.31 1.52 |
| Daily Volume: | 1,144,228 |
| Market Cap: | US$529.470M |
December 10, 2024 November 07, 2024 October 31, 2024 October 11, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
